Table 1.

Individual data regarding clinical bleeding, ultrasonography imaging, renal failure and treatment (NA = not available)

Patient number (sex, age)	Time before presentation	Clinical hemorrhage	USG signs	Internal blood volume (mL)	Antivenom doses	Renal failure
1 (M, 12)	6–24 h	Yes	Yes	2000	2	No
2 (M, 21)	6–24 h	No	Yes	190	1	No
3 (M, 19)	6–24 h	No	No	0	2	No
4 (M, 40)	>72 h	Yes	Yes	58	4	Yes
5 (F, 26)	6–24 h	Yes	Yes	90	2	No
6 (F, 13)	>72 h	Yes	Yes	NA	1	No
7 (F, 12)	<6 h	Yes	Yes	12	2	No
8 (F, 40)	24–48 h	No	Yes	NA	1	No
9 (M, 33)	>72 h	No	No	65	1	No
10 (F, 25)	48–72 h	No	Yes	NA	0	No
11 (M, 70)	<6 h	No	No	1200	1	No
12 (M, 10)	<6 h	Yes	Yes	NA	2	No
13 (M, 12)	6–24 h	Yes	No	72	1	No
14 (M, 30)	>72 h	Yes	Yes	NA	3	Yes
15 (M, 30)	>72 h	Yes	Yes	NA	3	No
16 (M, 35)	6–24 h	No	No	340	2	No
17 (F, 40)	48–72 h	Yes	Yes	13	3	No
18 (M, 32)	>72 h	No	No	0	1	No
19 (M, 40)	>72 h	Yes	No	0	2	No
20 (F, 35)	<6 h	Yes	No	0	1	No
21 (M, 28)	48–72 h	Yes	Yes	320	3	No
22 (M,17)	<6 h	No	No	0	1	No
23 (F, 30)	>72 h	No	Yes	NA	0	No
24 (F, 22)	6–24 h	No	No	0	1	No
25 (M, 24)	48–72 h	Yes	Yes	NA	2	No
26 (M, 10)	>72 h	No	Yes	184	2	No
27 (M, 19)	24–48 h	Hematuria	Yes	60	2	No
28 (F,28)	6–24 h	No	No	0	1	No
29 (M, 40)	24–48 h	No	No	0	1	No
30 (M, 28)	6–24 h	No	No	0	1	No
31 (M, 11)	>72 h	Yes	Yes	450	4	No
32 (M, 25)	>72 h	No	Yes	NA	2	No